Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 34, 2024 - Issue 3
Submit an article Journal homepage
250
Views
1
CrossRef citations to date
0
Altmetric
Review

Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 2023

Kyle D. ReichlOncology R&D, AstraZeneca, Waltham, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7779-0846View further author information
ORCID Icon,
Esther C. Y. LeeOncology R&D, AstraZeneca, Waltham, MA, USAORCID Iconhttps://orcid.org/0000-0003-0329-9186View further author information
ORCID Icon &
Ariamala GopalsamyOncology R&D, AstraZeneca, Waltham, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3704-3891View further author information
ORCID Icon
Pages 159-169 | Received 21 Dec 2023, Accepted 28 Mar 2024, Published online: 05 Apr 2024

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.